Performance awards lift Nu Skin (NYSE: NUS) EVP’s holdings to 128,332 shares

Rhea-AI Filing Summary

Nu Skin Enterprises executive Justin S. Keisel reported stock awards tied to performance goals. On February 10, 2026, he acquired 2,910 shares of Class A common stock at $0.00 per share, increasing his direct holdings to 93,832 shares.

On the same date, he acquired an additional 34,500 shares at $0.00 per share, bringing his direct ownership to 128,332 shares. Both grants relate to previously awarded restricted stock units that became eligible for vesting after Nu Skin met specified performance criteria from 2024 and 2025 grants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keisel Justin S

(Last) (First) (Middle)

C/O NU SKIN ENTERPRISES, INC.

75 W CENTER STREET

(Street)

PROVO UT 84601

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NU SKIN ENTERPRISES, INC. [ NUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, President of Global Sales

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/10/2026		A		2,910(1)	A	$0.00	93,832	D
Class A Common Stock	02/10/2026		A		34,500(2)	A	$0.00	128,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 27, 2024, the reporting person was granted restricted stock units, the vesting of which was contingent on Nu Skin Enterprises, Inc.'s satisfaction of certain performance criteria. On February 10, 2026, the performance criteria were met, resulting in the amount shown above becoming eligible for vesting.

2. On February 26, 2025, the reporting person was granted restricted stock units, the vesting of which was contingent on Nu Skin Enterprises, Inc.'s satisfaction of certain performance criteria. On February 10, 2026, the performance criteria were met, resulting in the amount shown above becoming eligible for vesting.

	/s/ Gregory Belliston as Attorney-in-Fact for Justin Keisel	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Justin S. Keisel report for NUS?

Justin S. Keisel reported acquiring Class A common stock in Nu Skin. He received 2,910 shares at $0.00 per share, then 34,500 additional shares, also at $0.00, as performance-based awards, raising his direct holdings to 128,332 shares.

How many Nu Skin (NUS) shares does Justin S. Keisel now directly own?

After the reported transactions, Justin S. Keisel directly owns 128,332 Nu Skin Class A shares. His holdings increased through two performance-based stock awards that became eligible for vesting once Nu Skin’s previously defined performance criteria were satisfied.

What was the price of the Nu Skin (NUS) shares acquired by Justin S. Keisel?

The reported Nu Skin shares were acquired at $0.00 per share. These were not open-market purchases but stock awards linked to restricted stock units that became eligible for vesting after Nu Skin met specified performance conditions from earlier grant dates.

What type of equity awards did Justin S. Keisel receive from Nu Skin (NUS)?

Justin S. Keisel received shares underlying performance-based restricted stock units. Awards granted in 2024 and 2025 became eligible for vesting on February 10, 2026, when Nu Skin satisfied the performance criteria, resulting in the reported share acquisitions at no cash cost.

What is Justin S. Keisel’s role at Nu Skin (NUS) in this Form 4?

In this Form 4, Justin S. Keisel is identified as an officer of Nu Skin, serving as EVP, President of Global Sales. The reported transactions reflect changes in his direct equity ownership through performance-based stock awards rather than market purchases or sales.